Shares of Panacea Biotec surged 9 per cent to Rs 411 on the BSE in the intra-day trade on Monday after the company announced that it has received a manufacturing license to produce Sputnik V vaccine at its Baddi (Himachal Pradesh) plant. The stock of one of the leading vaccine and pharmaceutical producers in India had hit a 52-week high of Rs 453.70 on May 28, 2021.
"The company announces receipt of manufacturing license from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund). The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India," Panacea Biotec said in a press release on Sunday, July 4, 2021.
Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021. Sputnik V has been registered in 67 countries globally, covering a total population of over 3.5 billion people.
At 10:25 am, the stock was up 6 per cent at Rs 399 on the BSE as compared to a 0.65 per cent rise in the S&P BSE Sensex. Trading volumes on the counter nearly doubled with a combined around 647,000 shares having changed hands on the NSE and BSE till the time of writing of this report.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU